Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Neoadjuvant SOX + bevacizumab followed by organ-preserving TME for unresectable rectal cancer
jRCTs021180023Phase 2Completed
- Start
- Apr 2018
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of tegafur, oxaliplatin and bevacizumab in rectal cancer. Primary endpoint: T down-staging rate. Started Apr 2018; status: completed.
02
Drugs
tegafuroxaliplatinbevacizumab
03
Conditions
rectal cancer
Beyond the preview
Go deeper on jRCTs021180023.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCTs021180023.